Sunday 18 October 2026
Export PRLD’s income statement to Excel — free account
Prelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.26
0.06
−1.81%
Follow PRLD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
23.39 | 13.62 | 11.66 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.67) | (13.01) | 9.65 | (5.74) | |
P/B ratio |
3.92 | 4.69 | 3.25 | 1.87 | |
Price to Tangible BV |
3.92 | 4.69 | 3.25 | 1.87 | |
EV/Sales |
16.62 | 9.68 | 6.27 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.21) | (4.59) | (2.13) | (0.55) | |
EV/FCF |
(11.18) | (4.58) | (2.13) | (0.55) | |
Quick Ratio |
3.99 | 1.95 | 1.95 | 3.02 | |
Current Ratio |
4.07 | 2.03 | 1.99 | 3.21 | |
Net Debt/EBITDA |
9.85 | 5.75 | 6.03 | 2.74 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.15 | 0.16 | 0.12 | 0.00 | |
Operating CF/Net income |
1.12 | 2.09 | (1.40) | 0.97 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
282.80% | 296.97% | 319.01% | 333.97% | |
Selling, General and Administrative Expense of Revenue |
88.13% | 112.58% | 88.58% | 80.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
35.54% | 43.67% | 32.70% | 37.28% | |
Graham Net Nets |
0.19 | 0.09 | 0.15 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.70%) | (29.24%) | (44.48%) | (102.08%) | |
Free Cash Flow Yield |
(6.35%) | (15.53%) | (25.26%) | (91.48%) | |
Revenue per Share |
0.06 | 0.06 | 0.07 | 0.09 | |
Operating CF per Share |
(0.16) | (0.26) | 0.30 | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.26) | 0.30 | (0.25) | |
Cash per Share |
1.54 | 0.99 | 1.34 | 0.72 | |
Shareholders Equity per Share |
1.36 | 0.73 | 0.89 | 0.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.36 | 0.73 | 0.89 | 0.77 | |
Free Cash Flow |
(15.57) | (21.68) | 23.12 | (19.11) | |
Working Capital |
116.86 | 42.87 | 52.70 | 40.14 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
99.27 | 25.13 | 33.01 | 22.11 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.50 | 3.95 | 5.86 | 4.23 | |
Average Assets |
152.14 | 130.45 | 158.42 | 145.99 | |
Average Common Equity |
104.79 | 81.68 | 100.05 | 107.48 |
Columns are period end dates